DDInter1002 DDInter1625
Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration.
Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).
Ixazomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vibrio cholerae CVD 103-HgR strain live antigen
Ixazomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Filgrastim
Ixazomib {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Ixazomib {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Ixazomib may lead to a major life threatening interaction when taken with Clozapine
Ixazomib may lead to a major life threatening interaction when taken with Rotavirus vaccine